aura6000 system
LivaNova USA, Inc. · Decision date Mar 18, 2026
What did the FDA approve?
FDA records P250013 as an original PMA application. The recorded decision is approval, dated Mar 18, 2026.
FDA approval order statement
Approval for the aura6000 system, which includes the Implantable Pulse Generator Model #100.0100, Lead Models #300.0100 (25cm) and #300.0200 (33cm), Remote Control & Charger Model #500.0100, Charging Antenna Model #500.0300, aura Clinical Manager Model #700.0100, Torque Wrench, and Suture Sleeve. The device is indicated for the reduction of apneas, hypopneas, or both in adult patients with moderate to severe obstructive sleep apnea (OSA), defined as an apnea-hypopnea index (AHI) of = 15 and = 65. The aura6000 system is intended for patients who failed, do not tolerate, or are ineligible to be treated with current standard of care treatments such as positive airway pressure (PAP), oral appliances (e.g. mandibular advancement device), or pharmacotherapy. PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or Unwillingness to use PAP (e.g., a patient returns the PAP system after attempting to use it).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Anesthesiology
- Decision date
- Mar 18, 2026
Regulatory record facts
- Identifier
- P250013
- Regulatory pathway
- Premarket approval application
- Applicant
- LivaNova USA, Inc.
- Product code
- MNQ
- Decision code
- APPR
- Decision date
- Mar 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.
- Applicant
- LivaNova USA, Inc.
- Product code
- MNQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250013 received
Application receipt date recorded by FDA.
P250013 · FDA decision
APPR
P250013/S001 · Related supplement
aura6000 system
P250013/S002 · Related supplement
aura6000 system
Timeline entries are records held by MedtechLedger for P250013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
aura6000 systemP250013/S001 | LivaNova USA, Inc. | PMA supplement | Apr 30, 2026 | FDA |
aura6000 systemP250013/S002 | LivaNova USA, Inc. | PMA supplement | Jun 18, 2026 | FDA |
Explore the linked device profile
Other records with product code MNQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Model 4063 Dedicated Tray SealerP130008/S148 | Inspire Medical Systems | PMA supplement | Nov 5, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S144 | Inspire Medical Systems | PMA supplement | Oct 26, 2026 | FDA |
Model 3150 IPGP130008/S147 | Inspire Medical Systems | PMA supplement | Oct 22, 2026 | FDA |
Model 3150 IPGP130008/S146 | Inspire Medical Systems | PMA supplement | Oct 13, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S123 | Inspire Medical Systems | PMA supplement | Aug 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P250013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





